Entrada Therapeutics, Inc. (TRDA)
5.25
+0.56
(+11.94%)
USD |
NASDAQ |
Nov 10, 16:00
5.255
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Shareholders Equity (Quarterly) : 198.32M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 198.32M |
| June 30, 2026 | 233.41M |
| March 31, 2026 | 270.85M |
| December 31, 2025 | 306.13M |
| September 30, 2025 | 340.72M |
| June 30, 2025 | 379.50M |
| March 31, 2025 | 417.26M |
| December 31, 2024 | 428.68M |
| September 30, 2024 | 422.45M |
| June 30, 2024 | 429.92M |
| March 31, 2024 | 269.37M |
| December 31, 2023 | 242.36M |
| Date | Value |
|---|---|
| September 30, 2023 | 246.66M |
| June 30, 2023 | 206.91M |
| March 31, 2023 | 229.61M |
| December 31, 2022 | 212.55M |
| September 30, 2022 | 233.22M |
| June 30, 2022 | 256.04M |
| March 31, 2022 | 277.39M |
| December 31, 2021 | 298.72M |
| September 30, 2021 | 124.90M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 40.17M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Prime Medicine, Inc. | 39.81M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.529B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 266.88M |
| Total Liabilities (Quarterly) | 68.56M |
| Debt to Equity Ratio | 0.2386 |
| Current Ratio | 7.847 |
| Net Debt Paydown Yield | 0.60% |